Distinctive differences in multiple sclerosis (MS) have been observed by race and ethnicity. We aim to (1) assess how often race and ethnicity were reported in clinical trials registered on ClinicalTrials.gov, (2) evaluate whether the population was diverse enough, and (3) compare with publications.
Methods:
We included phase 3 clinical trials registered with results on ClinicalTrials.gov between 2007 and 2023. When race and/or ethnicity were reported, we searched for the corresponding publications.
Results:
Out of the 99 included studies, 56% reported race and/or ethnicity, of which only 26% of those primarily completed before 2017. Studies reporting race or ethnicity contributed to a total of 33,891 participants, mainly enrolled in Eastern Europe. Most were White (93%), and the median percentage of White participants was 93% (interquartile range (IQR) = 86%–98%), compared to 3% for Black (IQR = 1%–12%) and 0.2% for Asian (IQR = 0%–1%). Four trials omitted race and ethnicity in publications and even when information was reported, some discrepancies in terminology were identified and categories with fewer participants were often collapsed.
Conclusion:
More efforts should be done to improve transparency, accuracy, and representativeness, in publications and at a design phase, by addressing social determinants of health that historically limit the enrollment of underrepresented population.
OntanedaDAmezcuaL. Re-thinking race and geography in multiple sclerosis. Mult Scler J2024; 30(1): 16–18.
2.
Langer-GouldABraraSMBeaberBE, et al. Incidence of multiple sclerosis in multiple racial and ethnic groups. Neurology2013; 80: 1734–1739.
3.
WallinMTCulpepperWJCoffmanP, et al. The Gulf War era multiple sclerosis cohort: Age and incidence rates by race, sex and service. Brain2012; 135(Pt 6): 1778–1785.
4.
Langer-GouldAMGonzalesEGSmithJB, et al. Racial and ethnic disparities in multiple sclerosis prevalence. Neurology2022; 98: e1818.
5.
AmezcuaLMcCauleyJL. Race and ethnicity on MS presentation and disease course. Mult Scler2020; 26(5): 561–567.
6.
PérezCALincolnJA. Racial and ethnic disparities in treatment response and tolerability in multiple sclerosis: A comparative study. Mult Scler Relat Disord2021; 56: 103248.
DobsonRRiceDRD’hoogheM, et al. Social determinants of health in multiple sclerosis. Nat Rev Neurol2022; 18: 723–734.
9.
PaganoMGauvreauK. Principles of biostatistics. Boca Raton, FL; London; New York: CRC Press, Taylor & Francis Group, 2018.
10.
MarrieRAChatawayJBiererBE, et al. Enhancing diversity of clinical trial populations in multiple sclerosis. Mult Scler2023; 29(9): 1174–1185.
11.
ZarinDATseTWilliamsRJ, et al. Trial reporting in ClinicalTrials.gov—The final rule. N Engl J Med2016; 375: 1998–2004.
12.
FainKMNelsonJTTseT, et al. Race and ethnicity reporting for clinical trials in ClinicalTrials.gov and publications. Contemp Clin Trials2021; 101: 106237.
LewisCCohenPRBahlD, et al. Race and ethnic categories: A brief review of global terms and nomenclature. Cureus2023; 15(7): e41253.
17.
OnuorahH-MCharronOMeltzerE, et al. Enrollment of non-White participants and reporting of race and ethnicity in phase III trials of multiple sclerosis DMTs: A systematic review. Neurology2022; 98: e880–e892.
18.
Novartis Pharmaceuticals. A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of siponimod (BAF312) in patients with secondary progressive multiple sclerosis followed by extended treatment with open-label BAF312, 2023, https://clinicaltrials.gov/study/NCT01665144
19.
KapposLBar-OrACreeBAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study. Lancet2018; 391: 1263–1273.
20.
Biogen. A phase 3 study in subjects with relapsing remitting multiple sclerosis to evaluate the tolerability of ALKS 8700 and dimethyl fumarate, 2020, https://clinicaltrials.gov/study/NCT03093324
21.
NaismithRTWundesAZiemssenT, et al. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing–remitting multiple sclerosis: Results from the randomized, double-blind, phase III EVOLVE-MS-2 study. CNS Drugs2020; 34(2): 185–196.
22.
SmalheiserNRHoltAW. A web-based tool for automatically linking clinical trials to their publications. J Am Med Inf Assoc2022; 29: 822–830.
23.
PageMJMcKenzieJEBossuytPM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ2021; 372: n71.
Pfizer’s Upjohn has merged with Mylan to form Viatris Inc. An open-label long-term study of pregabalin for the treatment of central neuropathic pain (post spinal cord injury pain, post stroke pain, and multiple sclerosis pain), 2021, https://clinicaltrials.gov/study/NCT01202227
26.
WelkB. A double blind, randomized placebo controlled trial evaluating the urodynamic and clinical efficacy of mirabegron among neurogenic bladder patients, 2019, https://clinicaltrials.gov/study/NCT02044510
27.
Ipsen. A phase III, multicentre, randomised, double blind, parallel group, placebo controlled study to assess the efficacy and safety of one or more intradetrusor treatments of 600 or 800 units of Dysport® for the treatment of urinary incontinence in subjects with neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis, 2022, https://clinicaltrials.gov/study/NCT02660138
28.
Ipsen. A phase III, multicentre, randomised, double blind, parallel group, placebo controlled study to assess the efficacy and safety of one or more intradetrusor treatments of 600 or 800 units of Dysport® for the treatment of urinary incontinence in subjects with neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis, 2022, https://clinicaltrials.gov/study/NCT02660359
29.
Avanir Pharmaceuticals. A double-blind, randomized, placebo-controlled, multicenter study to assess the safety and efficacy and to determine the pharmacokinetics of two doses of AVP-923 (dextromethorphan/quinidine) in the treatment of pseudobulbar affect (PBA) in patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), 2017, https://clinicaltrials.gov/study/NCT00573443
30.
NarasimhanM. An open-label, 8-week, flexible dose trial of escitalopram (Lexapro®) in comorbid major depression with amyotrophic lateral sclerosis and multiple sclerosis, 2019, https://clinicaltrials.gov/study/NCT00965497
VollmerTLRobinsonMJRisserRC, et al. A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis. Pain Pract2014; 14(8): 732–744.
34.
SørensenPSComiGVollmerTL, et al. Laquinimod safety profile. Int J MS Care2017; 19(1): 16–24.
35.
YapundichRApplebeeABethouxF, et al. Evaluation of dalfampridine extended release 5 and 10 mg in multiple sclerosis. Int J MS Care2015; 17(3): 138–145.
36.
KhanORieckmannPBoykoA, et al. Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosis. Ann Neurol2013; 73: 705–713.
37.
WolinskyJSBorresenTEDietrichDW, et al. GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord2015; 4: 370–376.
38.
CohenJAArnoldDLComiG, et al. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): A randomised, placebo-controlled, phase 2 trial. Lancet Neurol2016; 15(4): 373–381.
39.
ComiGKapposLSelmajKW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): A multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol2019; 18(11): 1009–1020.
40.
Bar-OrACalkwoodJCChognotC, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology2020; 95: e1999–e2008.
41.
CohenJAComiGSelmajKW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): A multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol2019; 18(11): 1021–1033.
42.
CreeBACGoldmanMDCorboyJR, et al. Efficacy and safety of 2 fingolimod doses vs glatiramer acetate for the treatment of patients with relapsing-remitting multiple sclerosis: A randomized clinical trial. JAMA Neurol2021; 78: 48.
43.
CohenJATenenbaumNBhattA, et al. Extended treatment with fingolimod for relapsing multiple sclerosis: The 14-year LONGTERMS study results. Ther Adv Neurol Disord2019; 12: 1756286419878324.
44.
ValenzuelaBOlsson GisleskogPPoggesiI, et al. An exposure-response analysis of ponesimod clinical efficacy in a randomized phase III study in patients with relapsing multiple sclerosis. CPT Pharmacometrics Syst Pharmacol2022; 11(10): 1294–1304.
45.
VollmerTLCohenJAAlvarezE, et al. Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. Mult Scler Relat Disord2020; 46: 102454.
46.
NaismithRTWolinskyJSWundesA, et al. Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Mult Scler2020; 26(13): 1729–1739.
47.
SamjooIAKlotzLGiovannoniG, et al. Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis. Mult Scler Relat Disord2022; 66: 104031.
48.
VermerschPOreja-GuevaraCSivaA, et al. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial. Eur J Neurol2022; 29(3): 790–801.
49.
GoldRArnoldDLBar-OrA, et al. Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results. Mult Scler2022; 28(5): 801–816.
50.
AmezcuaLMao-DraayerYVargasWS, et al. Efficacy of dimethyl fumarate in young adults with relapsing-remitting multiple sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE studies. Neurol Ther2023; 12(3): 883–897.
51.
CreeBACCutterGWolinskyJS, et al. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol2020; 19(12): 988–997.
52.
NourbakhshBRevirajanNMorrisB, et al. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: A randomised, placebo-controlled, crossover, double-blind trial. Lancet Neurol2021; 20(1): 38–48.
53.
CohenJACameronMHGoldmanMD, et al. A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment. Mult Scler2022; 28(5): 817–830.
54.
OkudaDTKantorDJarosM, et al. Arbaclofen extended-release tablets for spasticity in multiple sclerosis: Open-label extension study. Brain Commun2022; 5: fcad026.
55.
SteinmanLFoxEHartungH-P, et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med2022; 387: 704–714.
56.
CassardSDFitzgeraldKCQianP, et al. High-dose vitamin D3 supplementation in relapsing-remitting multiple sclerosis: A randomised clinical trial. eClinicalMedicine2023; 59: 101957.
57.
HemmerBWiendlHRothK, et al. Efficacy and safety of proposed biosimilar natalizumab (PB006) in patients with relapsing-remitting multiple sclerosis: The antelope phase 3 randomized clinical trial. JAMA Neurol2023; 80: 298.
58.
TurnerBESteinbergJRWeeksBT, et al. Race/ethnicity reporting and representation in US clinical trials: A cohort study. Lancet Reg Health Am2022; 11: 100252.
59.
GeorgeSDuranNNorrisK. A systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific Islanders. Am J Public Health2014; 104(2): e16–e31.
60.
WilliamsMJOkaiAFCrossAH, et al. Demographics and baseline disease characteristics of Black and Hispanic patients with multiple sclerosis in the open-label, single-arm, multicenter, phase IV CHIMES trial. Mult Scler Relat Disord2023; 76: 104794.
61.
ShamamboLJHenryTL. Rethinking the use of “Caucasian” in clinical language and curricula: A trainee’s call to action. J Gen Intern Med2022; 37(7): 1780–1782.
62.
RambachanA. Overcoming the racial hierarchy: The history and medical consequences of “Caucasian.”J Racial Ethn Health Disparities2018; 5(5): 907–912.
63.
AgyemangCBhopalRBruijnzeelsM. Negro, Black, Black African, African Caribbean, African American or what? Labelling African origin populations in the health arena in the 21st century. J Epidemiol Community Health2005; 59(12): 1014–1018.
64.
Committee on Improving the Representation of Women and Underrepresented Minorities in Clinical Trials and Research, Committee on Women in Science, Engineering, and Medicine, Policy and Global Affairs, & National Academies of Sciences, Engineering, and Medicine. Improving representation in clinical trials and research: Building research equity for women and underrepresented groups (26479). Washington, DC: National Academies Press, 2022.
65.
Cochrane handbook for systematic reviews of interventions. New York: Wiley, 2019.
66.
PageMJSterneJACHigginsJPT, et al. Investigating and dealing with publication bias and other reporting biases in meta-analyses of health research: A review. Res Synth Methods2021; 12(2): 248–259.
67.
TseTWilliamsRJZarinDA. Reporting “basic results” in ClinicalTrials.gov. Chest2009; 136(1): 295–303.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
